Drug Trial Radar · NCT07391215
5G-PEARL: Paxalisib in Malignant Brain Tumours
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Jan 19, 2026
Primary completion
Jan 19, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Institute of Cancer Research, United KingdomAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Minderoo Foundation; Kazia Therapeutics Limited; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cancer Research UK
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the safety and tolerability of paxalisib in combination with temozolomide and to determine the preliminary antitumour activity of the combination therapy. In the Phase 1b of this study parallel biomarker defined arms will be opened in the front-line unmethylated MGMT setting, enrolling 10 patients onto each arm. These patients will be treated with paxalisib in combination with temozolomide (TMZ). The starting dose of paxalisib will be 45mg once a day (OD) with the option of increasing to 60 mg (30 mg BD) in Cycle 2. TMZ will be administered once daily by mouth on days 1 to 5 in a 28-day cycle, with a starting dose of 150mg/m2 during cycles 1 and 2, and subsequent dose escalation to 200mg/m2 at the start of cycle 3 if cycles 1 and 2 have been well tolerated with no significant toxicity.
Conditions
- Malignant Primary Gliomas
- Glioblastoma Multiforme (GBM)
Interventions
PaxalisibDrug
Supplied as 15 mg capsules (35 capsules per bottle).
Temozolomide capsuleDrug
Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b - Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) in patients with malignant brain tumoursTime frame: 12 months
- Phase 1b - To determine the preliminary antitumour activity of the investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 12 months
- Phase 2 - To determine the antitumour activity of investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 24 months
- Phase 2 - To determine the antitumour activity of investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal Marden NHS Foundation Trust
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.